Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving NWTN Inc. and its officers or directors [1] Group 1: Company Developments - On May 28, 2025, NWTN disclosed that it received a determination notice from Nasdaq regarding the delisting of its securities [3] - Following the delisting news, NWTN's stock price dropped by $0.72 per share, representing a 32% decline, closing at $1.53 per share on May 30, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Redwire Corporation and its executives, following disappointing financial results and stock price decline [1][3]. Financial Performance - Redwire reported Q1 2025 revenue of $61.4 million, which was $13.14 million below consensus estimates, marking a 30.1% decline year-over-year [3]. - The company attributed the revenue shortfall to delays in U.S. government contract awards, linked to leadership transitions at agencies such as NASA and the Space Development Agency, as well as changing budget priorities under the Trump administration [3]. Stock Market Reaction - Following the release of the financial results, Redwire's stock price decreased by $0.75, or 6.63%, closing at $10.56 per share on May 12, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Travere Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On May 15, 2025, Travere announced that the FDA plans to hold an advisory committee meeting regarding its supplemental New Drug Application for FILSPARI, aimed at treating focal segmental glomerulosclerosis [3] - Following this announcement, Travere's stock price dropped by $4.35, or 20.57%, closing at $16.80 per share on May 16, 2025 [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Travere for claims related to potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Hallador Energy Company and its officers or directors [1] Group 1: Company Developments - On May 23, 2025, Hallador announced the termination of its exclusivity agreement with a datacenter developer regarding a potential power supply deal, leading to ongoing discussions for a new exclusivity period and evaluations of opportunities with other parties [3] - Following the announcement, Hallador's stock price decreased by $1.38 per share, or 7.33%, closing at $17.45 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is actively seeking claims from investors of Hallador Energy Company, indicating a serious investigation into possible securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of recovering significant damages for victims of securities fraud [4]

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Tempus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 28, 2025, S ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Luminar Technologies, Inc. and its officers or directors [1] Group 1: Company Developments - On May 14, 2025, Luminar announced the resignation of founder Austin Russell as President and CEO, as well as Chairperson of the Board, following an inquiry by the Audit Committee regarding the Code of Business Conduct and Ethics [3] - Following the announcement of Russell's resignation, Luminar's stock price dropped by $0.80 per share, representing a decline of 16.81%, closing at $3.96 per share on May 15, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of advocating for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Semler Scientific Inc. and its officers or directors [1] Company Summary - Semler Scientific Inc. filed its annual report for 2024 on February 28, 2025, indicating a risk of a civil complaint from the U.S. Department of Justice related to the False Claims Act [3] - The company received an initial civil investigative demand from the DOJ in July 2017 concerning reimbursement claims for its QuantaFlo device [3] - Settlement discussions with the DOJ in February 2025 were unsuccessful [3] Market Reaction - Following the news of the investigation and potential legal issues, Semler's stock price dropped by $4.03 per share, or 9.4%, closing at $38.89 per share on March 3, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Savara Inc. and its officers or directors following a significant stock price drop after an FDA refusal letter [1][3]. Group 1: Company Overview - Savara Inc. is a publicly traded company on NASDAQ under the ticker SVRA [1]. - The company recently announced it received a refusal to file letter from the FDA regarding its Biologics License Application for MOLBREEVI, a therapy aimed at treating autoimmune PAP [3]. Group 2: Stock Performance - Following the FDA news, Savara's stock price decreased by $0.90 per share, representing a decline of 31.69%, closing at $1.94 per share on May 27, 2025 [3]. Group 3: Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is leading the investigation into Savara's potential misconduct [1][4]. - The firm has a history of recovering significant damages for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving NeuroPace, Inc. and its officers or directors [1] Group 1: Company Performance - On May 27, 2025, NeuroPace announced the preliminary one-year results of the NAUTILUS study, which evaluated the safety and effectiveness of the RNS System for treating drug-resistant idiopathic generalized epilepsy (IGE) [3] - The study did not achieve statistical significance for its primary effectiveness endpoint, which aimed to demonstrate a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group [3] - Following the announcement, NeuroPace's stock price dropped by $5.02 per share, or 28.39%, closing at $12.66 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of NeuroPace to gather information regarding potential claims related to securities fraud [1] - The firm has a long history in corporate, securities, and antitrust class litigation, having recovered numerous multimillion-dollar damages awards for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged securities fraud and unlawful business practices, with a deadline for investors to join the lawsuit by July 22, 2025 [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Organon and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased or acquired Organon securities during the Class Period are advised to contact Pomerantz LLP to potentially become Lead Plaintiff [2]. Group 2: Financial Performance - On May 1, 2025, Organon reported a significant reduction in its dividend payout from $0.28 to $0.02, indicating a shift in capital allocation priorities to focus on deleveraging [4]. - Following the announcement of the dividend cut, Organon's stock price dropped by $3.48 per share, or 26.91%, closing at $9.45 per share on the same day [4].